All Antibody articles
-
NewsBillionaire professor donates ‘transformative’ sum to protein science institute
$210 million endowment from entrepreneur and Moderna investor Tim Springer will support ongoing research
-
Business
US supreme court confirms Amgen’s cholesterol antibody patents invalid
Decision could mean patent descriptions need to be even more detailed, and hence expensive
-
Opinion
Regulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
Business
Merck & Co to buy immunology specialist Prometheus
$10.8 billion cash deal give Merck rights to late-stage candidate for two inflammatory bowel conditions
-
Business
Second Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
Business
Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
Business
Protective treatment for Covid-19 makes minimal impact
Limited uptake of antibody combination for vulnerable patients, while demand for antivirals seems to be slowing
-
Opinion
Alzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
-
Feature
The incredible antibodies of sharks, llamas and camels
Sharks and llamas share a strange quirk of their immune systems. Hayley Bennett finds out how their ‘nanobodies’ could help us tackle Covid and a host of other diseases
-
Opinion
When regulatory cooperation goes too far, we all lose
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
-
Research
Engineered antibody that snags sperm could be an effective non-hormonal contraceptive
Approach could offer new method of contraception for women
-
Business
Regeneron’s Covid-19 antibodies help those who can’t make their own
Regn-Cov2 reduces deaths and shortens hospitalisation for these patients, even when given at late stages of infection
-
Business
Alzheimer’s antibody gets surprise US approval
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
-
Opinion
The side effects of being unique
Even the largest clinical trials won’t capture all possible bad reactions to a drug – we need pharmacovigilance
-
Business
Coronavirus variants stymie success of monoclonal antibodies
Lab-made antibodies can treat and protect people from Covid-19 but are more likely to succeed when administered as a cocktail
-
News
UK government faces lawsuit over procurement of Covid immunity test
The health department reportedly knew that the antibody test did not perform as well as claimed when it bought them
-
Business
Regulatory panel unconvinced by Alzheimer’s antibody evidence
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
-
Opinion
Blood offering
Antibodies in various forms could bridge the Covid-19 treatment gap until a vaccine is available
-
Business
Drop in plasma donations hits immunoglobulin supply
Lockdown and social distancing have discouraged donors, and the potential impact of convalescent plasma collection for Covid-19 treatment is unclear
-
Business
What are the risks of fast-tracking a Covid-19 vaccine?
Condensing timelines from years to months inevitably involves compromises
